A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2
about
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replicationAnimal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Prodrugs of phosphonates and phosphates: crossing the membrane barrierHSV neutralization by the microbicidal candidate C5AConformational analysis, molecular structure and solid state simulation of the antiviral drug acyclovir (zovirax) using density functional theory methods.Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture.Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirinShort communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovirMicrobicides: still a long road to successDrug transporter pharmacogenetics in nucleoside-based therapies.Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention.Virtual screening of acyclovir derivatives as potential antiviral agents: design, synthesis and biological evaluation of new acyclic nucleoside ProTides.
P2860
Q24634299-2A1F855D-8511-4DE1-A1C5-7E43565F9FDDQ26777022-8BC78C73-7833-4668-A34F-0A0F45D89963Q27005712-E0A2CBF4-E843-4BE3-BD9E-48EBCB437EFCQ28478074-87EA8C06-2A10-4530-B03D-01777CB1C0ADQ33833712-20A4FC3A-E448-42B4-A124-94231FD983E1Q33983315-85618F6D-0C00-43DB-BD9B-7B64CFFBB2C7Q34566597-58479B1E-381A-490F-9036-E155288B2E27Q35531731-E4281EFA-ED09-4DC2-96DF-6191506E8597Q35739055-00F99256-98AC-470F-AFE9-D3631AF5EE7FQ35941302-C1CCAE95-982B-4C2F-A859-B396A0F9D250Q36509679-E1E98049-0DD3-4FE0-9472-7523F3D8C30AQ37130757-7302B00A-328A-4BA7-91D4-7D5B90397498Q37760954-71B0F475-C78A-4389-B113-05938BCB1A34Q38049148-A1789B4D-6818-43A4-96EF-B2B470DCAC29Q40075273-DE1C0281-02BC-4DB5-9A25-3BED74A74AF1
P2860
A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@ast
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@en
type
label
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@ast
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@en
prefLabel
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@ast
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@en
P2093
P2860
P50
P356
P1476
A new class of dual-targeted a ...... nd herpes simplex virus type 2
@en
P2093
Andrea Lisco
Beda Brichacek
Christophe Vanpouille
Christopher McGuigan
Elisa Saba
Francesca Scrimieri
Leonid Margolis
Marco Derudas
P2860
P304
P356
10.1086/650343
P407
P577
2010-02-01T00:00:00Z